Compare DexCom, Inc. (DXCM) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Oatly Group AB - ADR — how do they compare? DexCom, Inc. trades at $83.9 (market cap $31.86B), while Oatly Group AB - ADR trades at $10.52 (market cap $330.93M). The key difference: DexCom, Inc. is far larger — about 96.3× Oatly Group AB - ADR's market cap, and DexCom, Inc. is trading nearer its 52-week high, Oatly Group AB - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Oatly Group AB - ADR for 18 Days on average.
| DXCM | OTLY | |
|---|---|---|
Market Cap | $31.86B | $330.93M |
Volume | 3,607,070 | 68,708 |
Sector | Health | Consumer Staples |
52-Week High | $92.34 | $15.91 |
52-Week Low | $54.84 | $8.03 |
Typical Hold Time | 62 Days | 18 Days |
Enterprise Value | $31.32B | $835.34M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
Oatly (OTLY) trades at $10.42, up 0.48% on the day, amid mixed technical signals and ongoing fundamental challenges. The stock shows a bearish moving average trend but bullish oscillators, with key support at $10. Revenue growth is steady, reaching $862.46M in 2025, yet profitability remains elusive with a net income margin of -13.81%. Recent Q2 2026 results beat expectations, and management raised full-year revenue guidance, driving positive sentiment from some analysts.
The outlook is cautiously optimistic, with a consensus price target of $12.28 suggesting 18% upside, but significant risks persist. High debt levels, negative cash flows, and intense competition in the plant-based food sector threaten near-term stability. Investors should weigh the potential for operational turnaround against persistent losses and leverage concerns before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
